Vanda Pharmaceuticals Inc. (VNDA) Reaches $16.98 After 6.00% Up Move; Orion Energy Systems, (OESX) Covered By 3 Bullish Analysts Last Week

February 15, 2018 - By Peter Erickson

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 7.10% or $1.125 during the last trading session, reaching $16.975. About 194,914 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since February 15, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.The move comes after 8 months positive chart setup for the $762.64M company. It was reported on Feb, 15 by Barchart.com. We have $17.99 PT which if reached, will make NASDAQ:VNDA worth $45.76 million more.

Among 5 analysts covering Orion Energy Systems (NASDAQ:OESX), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Orion Energy Systems had 10 analyst reports since August 4, 2015 according to SRatingsIntel. Roth Capital downgraded Orion Energy Systems, Inc (NASDAQ:OESX) on Tuesday, August 4 to “Buy” rating. Roth Capital maintained it with “Hold” rating and $1.0 target in Thursday, October 5 report. As per Tuesday, August 4, the company rating was downgraded by TH Capital. The stock of Orion Energy Systems, Inc (NASDAQ:OESX) earned “Buy” rating by H.C. Wainwright on Friday, May 26. The firm has “Hold” rating by Roth Capital given on Wednesday, February 7. The firm has “Hold” rating by Zacks given on Wednesday, September 2. On Friday, June 9 the stock rating was maintained by H.C. Wainwright with “Buy”. Roth Capital maintained it with “Hold” rating and $1.3000 target in Friday, June 9 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, August 7. Rodman & Renshaw initiated the shares of OESX in report on Monday, July 18 with “Buy” rating. See Orion Energy Systems, Inc (NASDAQ:OESX) latest ratings:




07/02/2018 Broker: Roth Capital Rating: Hold New Target: $0.85 Maintain
05/10/2017 Broker: Roth Capital Rating: Hold New Target: $1.0 Maintain

The stock decreased 1.77% or $0.015 during the last trading session, reaching $0.835. About 9,906 shares traded. Orion Energy Systems, Inc (NASDAQ:OESX) has risen 9.45% since February 15, 2017 and is uptrending. It has underperformed by 7.25% the S&P500.

Investors sentiment decreased to 0.69 in Q3 2017. Its down 0.07, from 0.76 in 2017Q2. It turned negative, as 4 investors sold Orion Energy Systems, Inc shares while 9 reduced holdings. 4 funds opened positions while 5 raised stakes. 12.79 million shares or 0.47% less from 12.85 million shares in 2017Q2 were reported. Blackrock invested in 0% or 82,069 shares. Dimensional Fund Advsr L P holds 0% of its portfolio in Orion Energy Systems, Inc (NASDAQ:OESX) for 307,250 shares. Wells Fargo And Mn holds 0% or 59,165 shares in its portfolio. Connors Investor accumulated 136,744 shares or 0.02% of the stock. Tower Rech Capital Ltd Llc (Trc) reported 0% in Orion Energy Systems, Inc (NASDAQ:OESX). Grace And White Ny has invested 0% in Orion Energy Systems, Inc (NASDAQ:OESX). State Street Corp holds 0% of its portfolio in Orion Energy Systems, Inc (NASDAQ:OESX) for 10,800 shares. North Star Investment Mngmt invested in 0.41% or 2.89 million shares. Ariel Invs Ltd Liability Co has 5.03 million shares. Guggenheim Ltd Llc holds 13,372 shares. 20,300 were accumulated by Raymond James Fin Svcs Advisors. Comml Bank Of Mellon Corporation owns 0% invested in Orion Energy Systems, Inc (NASDAQ:OESX) for 63,777 shares. Bank & Trust Of America De has 0% invested in Orion Energy Systems, Inc (NASDAQ:OESX). Royal Bancorp Of Canada has invested 0% in Orion Energy Systems, Inc (NASDAQ:OESX). Optimum Advisors holds 40,000 shares or 0.02% of its portfolio.

Orion Energy Systems, Inc. researches, designs, develops, makes, implements, markets, and sells energy management systems for the commercial office and retail, area lighting, and industrial markets in North America. The company has market cap of $24.15 million. The firm operates in three divisions: Orion U.S. It currently has negative earnings. Markets Division, Orion Engineered Systems Division, and Orion Distribution Services Division.

Since January 2, 2018, it had 0 insider buys, and 4 insider sales for $3.36 million activity. On Tuesday, January 2 the insider Gulino Richard L. sold $157,565. Polymeropoulos Mihael Hristos also sold $2.93M worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Tuesday, January 2. $140,494 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were sold by Kelly James Patrick. 8,568 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares with value of $130,777 were sold by Birznieks Gunther.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals has $26.0 highest and $15 lowest target. $22.13’s average target is 30.37% above currents $16.975 stock price. Vanda Pharmaceuticals had 22 analyst reports since September 2, 2015 according to SRatingsIntel. Piper Jaffray maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Thursday, October 19. Piper Jaffray has “Buy” rating and $26.0 target. The rating was maintained by Oppenheimer with “Outperform” on Monday, October 30. As per Sunday, November 12, the company rating was maintained by Oppenheimer. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Piper Jaffray on Thursday, August 3. On Wednesday, September 2 the stock rating was maintained by Piper Jaffray with “Buy”. The company was maintained on Thursday, August 3 by Oppenheimer. The firm earned “Buy” rating on Tuesday, February 13 by Jefferies. The rating was reinitiated by Jefferies with “Buy” on Thursday, October 6. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Tuesday, June 27 by Piper Jaffray. The rating was maintained by Oppenheimer with “Buy” on Monday, January 8.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $762.64 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.